Cite
HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.
MLA
Zheqi Li, et al. “HER2 Heterogeneity and Treatment Response-Associated Profiles in HER2-Positive Breast Cancer in the NCT02326974 Clinical Trial.” Journal of Clinical Investigation, vol. 134, no. 7, Apr. 2024, pp. 1–17. EBSCOhost, https://doi.org/10.1172/JCI176454.
APA
Zheqi Li, Filho, O. M., Viale, G., dell’Orto, P., Russo, L., Goyette, M.-A., Kamat, A., Yardley, D. A., Abramson, V. G., Arteaga, C. L., Spring, L. M., Chiotti, K., Halsey, C., Waks, A. G., King, T. A., Lester, S. C., Bellon, J. R., Winer, E. P., Spellman, P. T., & Krop, I. E. (2024). HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial. Journal of Clinical Investigation, 134(7), 1–17. https://doi.org/10.1172/JCI176454
Chicago
Zheqi Li, Otto Metzger Filho, Giuseppe Viale, Patrizia dell’Orto, Leila Russo, Marie-Anne Goyette, Avni Kamat, et al. 2024. “HER2 Heterogeneity and Treatment Response-Associated Profiles in HER2-Positive Breast Cancer in the NCT02326974 Clinical Trial.” Journal of Clinical Investigation 134 (7): 1–17. doi:10.1172/JCI176454.